Meeting
2015 ASCO Annual Meeting
A phase Ib study of abemaciclib with therapies for metastatic breast cancer.
Authors
Sara M. Tolaney
Dana Farber Cancer Institute, Boston, MA
Sara M. Tolaney , Muralidhar Beeram , J. Thaddeus Beck , Alison Katherine Conlin , Elizabeth Claire Dees , Maura N. Dickler , Teresa L. Helsten , Paul R. Conkling , William Jeffery Edenfield , Donald A. Richards , P. Kellie Turner , Na Cai , Edward Michael Chan , Shubham Pant , Carlos Becerra , Kevin Kalinsky , Shannon Puhalla , Brent Neil Rexer , Howard A. Burris III, Matthew P. Goetz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT02057133
Citation
J Clin Oncol 33, 2015 (suppl; abstr 522)
DOI
10.1200/jco.2015.33.15_suppl.522
Abstract #
522
Poster Bd #
10
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy.
First Author: Kevin Kalinsky
Poster
2021 ASCO Annual Meeting
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor SHR6390 combined with pyrotinib and letrozole in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor positive (HR+) metastatic breast cancer (MBC): Phase Ib study results.
First Author: Jian Zhang
Poster
2015 ASCO Annual Meeting
Phase III study of Palbociclib in combination with Exemestane vs. Capecitabine, in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patients with Resistance to non-steroidal Aromatase inhibitors (NSAI): PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006)
First Author: Miguel Martin
Poster
2024 ASCO Breakthrough
OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for patients with ER+, HER2- advanced or metastatic breast cancer after endocrine therapy and CDK4/6 inhibitors.
First Author: Joohyuk Sohn